Linked Data API

Show Search Form

Search Results

1137390
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16997 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16998 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.303Zmore like thismore than 2019-07-15T10:23:54.303Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
star this property label Biography information for Baroness Morgan of Huyton more like this
1137391
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16998 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.243Zmore like thismore than 2019-07-15T10:23:54.243Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
star this property label Biography information for Baroness Morgan of Huyton more like this
1137392
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16999 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16998 more like this
star this property question first answered
less than 2019-07-15T10:23:54.35Zmore like thismore than 2019-07-15T10:23:54.35Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
star this property label Biography information for Baroness Morgan of Huyton more like this
1136759
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Cabinet Office more like this
star this property answering dept id 53 more like this
star this property answering dept short name Cabinet Office more like this
star this property answering dept sort name Cabinet Office more like this
star this property hansard heading Government Departments: Bain and Company more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many consultancy contracts they have with Bain &amp; Company, broken down by each government department. more like this
star this property tabling member printed
Lord Hain more like this
star this property uin HL16909 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>In order to enable government departments to quickly secure resource for critical work on preparations and implementation of EU exit at pace, the Cabinet Office have put in place a set of contracts for all government departments to access. This includes a contract with Bain and Co. The contracts have been published on contracts finder and spend under this arrangement is published monthly on GOV.UK titled ‘Central EU Exit Consultancy’.</p> more like this
star this property answering member printed Lord Young of Cookham more like this
star this property grouped question UIN HL16910 more like this
star this property question first answered
less than 2019-07-15T14:53:31.09Zmore like thismore than 2019-07-15T14:53:31.09Z
star this property answering member
57
star this property label Biography information for Lord Young of Cookham more like this
star this property tabling member
567
star this property label Biography information for Lord Hain more like this
1136760
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Cabinet Office more like this
star this property answering dept id 53 more like this
star this property answering dept short name Cabinet Office more like this
star this property answering dept sort name Cabinet Office more like this
star this property hansard heading Government Departments: Bain and Company more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether any government department has used Bain &amp; Company for any consultancy or advisory work since 2010. more like this
star this property tabling member printed
Lord Hain more like this
star this property uin HL16910 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>In order to enable government departments to quickly secure resource for critical work on preparations and implementation of EU exit at pace, the Cabinet Office have put in place a set of contracts for all government departments to access. This includes a contract with Bain and Co. The contracts have been published on contracts finder and spend under this arrangement is published monthly on GOV.UK titled ‘Central EU Exit Consultancy’.</p> more like this
star this property answering member printed Lord Young of Cookham more like this
star this property grouped question UIN HL16909 more like this
star this property question first answered
less than 2019-07-15T14:53:31.01Zmore like thismore than 2019-07-15T14:53:31.01Z
star this property answering member
57
star this property label Biography information for Lord Young of Cookham more like this
star this property tabling member
567
star this property label Biography information for Lord Hain more like this
1136423
star this property registered interest false more like this
star this property date less than 2019-07-02more like thismore than 2019-07-02
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain. more like this
star this property tabling member printed
Lord Jones of Cheltenham more like this
star this property uin HL16873 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-10more like thismore than 2019-07-10
star this property answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16874 more like this
HL16875 more like this
star this property question first answered
less than 2019-07-10T15:30:08.963Zmore like thismore than 2019-07-10T15:30:08.963Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name Impact_Assessment.pdf more like this
star this property title Impact_Assessment more like this
star this property tabling member
248
star this property label Biography information for Lord Jones of Cheltenham more like this
1136424
star this property registered interest false more like this
star this property date less than 2019-07-02more like thismore than 2019-07-02
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain. more like this
star this property tabling member printed
Lord Jones of Cheltenham more like this
star this property uin HL16874 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-10more like thismore than 2019-07-10
star this property answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16873 more like this
HL16875 more like this
star this property question first answered
less than 2019-07-10T15:30:09.023Zmore like thismore than 2019-07-10T15:30:09.023Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name Impact_Assessment.pdf more like this
star this property title Impact_Assessment more like this
star this property tabling member
248
star this property label Biography information for Lord Jones of Cheltenham more like this
1136425
star this property registered interest false more like this
star this property date less than 2019-07-02more like thismore than 2019-07-02
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis. more like this
star this property tabling member printed
Lord Jones of Cheltenham more like this
star this property uin HL16875 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-10more like thismore than 2019-07-10
star this property answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16873 more like this
HL16874 more like this
star this property question first answered
less than 2019-07-10T15:30:09.087Zmore like thismore than 2019-07-10T15:30:09.087Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name Impact_Assessment.pdf more like this
star this property title Impact_Assessment more like this
star this property tabling member
248
star this property label Biography information for Lord Jones of Cheltenham more like this
1136420
star this property registered interest false more like this
star this property date less than 2019-07-02more like thismore than 2019-07-02
star this property answering body
Department for International Trade more like this
star this property answering dept id 202 more like this
star this property answering dept short name International Trade more like this
star this property answering dept sort name International Trade more like this
star this property hansard heading EU External Trade: Mercosur more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the benefits of the EU–Mercosur trade agreement; and which commercial sectors in the UK are expected to benefit from this agreement. more like this
star this property tabling member printed
Baroness Crawley more like this
star this property uin HL16870 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-08more like thismore than 2019-07-08
star this property answer text <p>The EU-Mercosur trade agreement reached political conclusion on 28 June 2019. This means that we have yet to receive the final text, which would be needed to assess the impacts of the final negotiated outcome, including which commercial sectors would benefit. This text is unlikely to be available for some time since the EU and Mercosur are still finalising the details of the agreement, which will then need to undergo legal review and official translation.</p><p>We welcome the news of political conclusion between the EU and Mercosur on a Free Trade Agreement. As a global champion of trade, the UK has been a strong advocate for these negotiations. The UK has longstanding positive bilateral relationships with individual Mercosur countries and we look forward to deepening our trading ties as we leave the EU. We will be working with our Mercosur partners to develop our future trade relationship in due course.</p> more like this
star this property answering member printed Viscount Younger of Leckie more like this
star this property grouped question UIN HL16871 more like this
star this property question first answered
less than 2019-07-08T16:22:47.843Zmore like thismore than 2019-07-08T16:22:47.843Z
star this property answering member
4169
star this property label Biography information for Viscount Younger of Leckie more like this
star this property tabling member
3386
star this property label Biography information for Baroness Crawley more like this
1136421
star this property registered interest false more like this
star this property date less than 2019-07-02more like thismore than 2019-07-02
star this property answering body
Department for International Trade more like this
star this property answering dept id 202 more like this
star this property answering dept short name International Trade more like this
star this property answering dept sort name International Trade more like this
star this property hansard heading Trade Agreements: Mercosur more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to seek a trade agreement along similar lines to the EU–Mercosur trade agreement once the UK has departed the EU; if so, whether they have begun any such discussions with Argentina, Brazil, Paraguay and Uruguay; and when they expect any such negotiations to be concluded. more like this
star this property tabling member printed
Baroness Crawley more like this
star this property uin HL16871 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-08more like thismore than 2019-07-08
star this property answer text <p>The EU-Mercosur trade agreement reached political conclusion on 28 June 2019. This means that we have yet to receive the final text, which would be needed to assess the impacts of the final negotiated outcome, including which commercial sectors would benefit. This text is unlikely to be available for some time since the EU and Mercosur are still finalising the details of the agreement, which will then need to undergo legal review and official translation.</p><p>We welcome the news of political conclusion between the EU and Mercosur on a Free Trade Agreement. As a global champion of trade, the UK has been a strong advocate for these negotiations. The UK has longstanding positive bilateral relationships with individual Mercosur countries and we look forward to deepening our trading ties as we leave the EU. We will be working with our Mercosur partners to develop our future trade relationship in due course.</p> more like this
star this property answering member printed Viscount Younger of Leckie more like this
star this property grouped question UIN HL16870 more like this
star this property question first answered
less than 2019-07-08T16:22:47.907Zmore like thismore than 2019-07-08T16:22:47.907Z
star this property answering member
4169
star this property label Biography information for Viscount Younger of Leckie more like this
star this property tabling member
3386
star this property label Biography information for Baroness Crawley more like this